Anacor Pharmaceuticals Inc. was incorporated in the state of Delaware on Dec. 14, 2000. Anacor Pharmaceuticals Inc. has a market cap of $209.4 million; its shares were traded at around $5.11 with and P/S ratio of 17.20.
On June 18 and 19, Senior Vice President and CFO of Anacor Pharmaceuticals Inc. (ANAC, Financial) Geoffrey M. Parker bought 43,046 shares at an average price of $5.22. The total transaction amount was $224,239.
Geoffrey M. Parker has been serving as the position of Anacor Pharmaceutical Inc.’s CFO and senior vice president since September 2010. From 1997 to April 2009, Mr. Parker was a vice president, managing director and partner at Goldman Sachs Group Inc.
In addition to Parker’s buy, SVP Program Management Kirk R. Maples and Director Lucy Shapiro together bought 50,600 shares of ANAC stock in June, April and March.
Anacor Pharmaceuticals Inc. announced their 2013 first quarter fiscal results. The company reported net loss of $15.1 million and revenues of $1.7 million.
On June 18 and 19, Senior Vice President and CFO of Anacor Pharmaceuticals Inc. (ANAC, Financial) Geoffrey M. Parker bought 43,046 shares at an average price of $5.22. The total transaction amount was $224,239.
Geoffrey M. Parker has been serving as the position of Anacor Pharmaceutical Inc.’s CFO and senior vice president since September 2010. From 1997 to April 2009, Mr. Parker was a vice president, managing director and partner at Goldman Sachs Group Inc.
In addition to Parker’s buy, SVP Program Management Kirk R. Maples and Director Lucy Shapiro together bought 50,600 shares of ANAC stock in June, April and March.
Anacor Pharmaceuticals Inc. announced their 2013 first quarter fiscal results. The company reported net loss of $15.1 million and revenues of $1.7 million.
